FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282938802> ?p ?o ?g. }

• W4282938802 abstract "Abstract The antibody conjugate gemtuzumab ozogamicin (GO; Mylotarg ® ) provides targeted therapy of acute myeloid leukemia (AML), with recent approvals for patients with CD33-positive disease at diagnosis or relapse, as monotherapy or combined with chemotherapeutics. While its clinical efficacy is well documented, the molecular routes by which GO induces AML cell death warrant further analyses. We have earlier reported that this process is initiated via mitochondria-mediated caspase activation. Here we provide additional data, focusing on the involvement of caspase-2 in this mechanism. We show that this enzyme plays an important role in triggering apoptotic death of human AML cells after exposure to GO or its active moiety calicheamicin. Accordingly, the caspase-2 inhibitor z-VDVAD-fmk reduced GO-induced caspase-3 activation. This finding was validated with shRNA and siRNA targeting caspase-2, resulting in reduced caspase-3 activation and cleavage of poly [ADP-ribose] polymerase 1 (PARP-1). We previously demonstrated that GO-induced apoptosis included a conformational change of Bax into a pro-apoptotic state. Present data reveal that GO-treatment also induced Bid cleavage, which was partially reduced by caspase-2 specific inhibition while the effect on GO-induced Bax conformational change remained unaltered. In mononuclear cells isolated from AML patients that responded to GO treatment in vitro, processing of caspase-2 was evident, whereas in cells from an AML patient refractory to treatment no such processing was seen. When assessing diagnostic samples from 22 AML patients, who all entered complete remission (CR) following anthracycline-based induction therapy, and comparing patients with long versus those with short CR duration no significant differences in baseline caspase-2 or caspase-3 full-length protein expression levels were found. In summary, we demonstrate that GO triggers caspase-2 cleavage in human AML cells and that the subsequent apoptosis of these cells in part relies on caspase-2. These findings may have future clinical implications." @default.
• W4282938802 created "2022-06-16" @default.
• W4282938802 creator A5006855220 @default.
• W4282938802 creator A5011058774 @default.
• W4282938802 creator A5014733644 @default.
• W4282938802 creator A5025252728 @default.
• W4282938802 creator A5030761470 @default.
• W4282938802 creator A5045155025 @default.
• W4282938802 creator A5059179985 @default.
• W4282938802 creator A5071457269 @default.
• W4282938802 creator A5080920861 @default.
• W4282938802 creator A5087206674 @default.
• W4282938802 creator A5087555630 @default.
• W4282938802 date "2022-06-11" @default.
• W4282938802 modified "2023-10-09" @default.
• W4282938802 title "Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia" @default.
• W4282938802 cites W1968028322 @default.
• W4282938802 cites W1974249811 @default.
• W4282938802 cites W1980921389 @default.
• W4282938802 cites W1984547206 @default.
• W4282938802 cites W1987680504 @default.
• W4282938802 cites W1992291725 @default.
• W4282938802 cites W1997054509 @default.
• W4282938802 cites W1997879915 @default.
• W4282938802 cites W1998799043 @default.
• W4282938802 cites W2007192173 @default.
• W4282938802 cites W2011685332 @default.
• W4282938802 cites W2012173926 @default.
• W4282938802 cites W2012333728 @default.
• W4282938802 cites W2013658872 @default.
• W4282938802 cites W2025338891 @default.
• W4282938802 cites W2026636420 @default.
• W4282938802 cites W2035335770 @default.
• W4282938802 cites W2038679462 @default.
• W4282938802 cites W2039223287 @default.
• W4282938802 cites W2039444414 @default.
• W4282938802 cites W2042779695 @default.
• W4282938802 cites W2052626321 @default.
• W4282938802 cites W2055651767 @default.
• W4282938802 cites W2062853648 @default.
• W4282938802 cites W2065406906 @default.
• W4282938802 cites W2069849780 @default.
• W4282938802 cites W2080559728 @default.
• W4282938802 cites W2083542782 @default.
• W4282938802 cites W2084299345 @default.
• W4282938802 cites W2084509256 @default.
• W4282938802 cites W2088805436 @default.
• W4282938802 cites W2109777886 @default.
• W4282938802 cites W2109956888 @default.
• W4282938802 cites W2117074998 @default.
• W4282938802 cites W2127568389 @default.
• W4282938802 cites W2137881702 @default.
• W4282938802 cites W2139232922 @default.
• W4282938802 cites W2150188330 @default.
• W4282938802 cites W2151670058 @default.
• W4282938802 cites W2180487778 @default.
• W4282938802 cites W2340812234 @default.
• W4282938802 cites W2545758180 @default.
• W4282938802 cites W2557376185 @default.
• W4282938802 cites W2605815386 @default.
• W4282938802 cites W2625583949 @default.
• W4282938802 cites W2731917889 @default.
• W4282938802 cites W2765083951 @default.
• W4282938802 cites W2769788167 @default.
• W4282938802 cites W2803116026 @default.
• W4282938802 cites W2804514017 @default.
• W4282938802 cites W2944449480 @default.
• W4282938802 cites W2989202715 @default.
• W4282938802 cites W3189036983 @default.
• W4282938802 cites W4248537801 @default.
• W4282938802 doi "https://doi.org/10.1038/s41420-022-01071-9" @default.
• W4282938802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35690610" @default.
• W4282938802 hasPublicationYear "2022" @default.
• W4282938802 type Work @default.
• W4282938802 citedByCount "1" @default.
• W4282938802 countsByYear W42829388022022 @default.
• W4282938802 crossrefType "journal-article" @default.
• W4282938802 hasAuthorship W4282938802A5006855220 @default.
• W4282938802 hasAuthorship W4282938802A5011058774 @default.
• W4282938802 hasAuthorship W4282938802A5014733644 @default.
• W4282938802 hasAuthorship W4282938802A5025252728 @default.
• W4282938802 hasAuthorship W4282938802A5030761470 @default.
• W4282938802 hasAuthorship W4282938802A5045155025 @default.
• W4282938802 hasAuthorship W4282938802A5059179985 @default.
• W4282938802 hasAuthorship W4282938802A5071457269 @default.
• W4282938802 hasAuthorship W4282938802A5080920861 @default.
• W4282938802 hasAuthorship W4282938802A5087206674 @default.
• W4282938802 hasAuthorship W4282938802A5087555630 @default.
• W4282938802 hasBestOaLocation W42829388021 @default.
• W4282938802 hasConcept C10205521 @default.
• W4282938802 hasConcept C12519072 @default.
• W4282938802 hasConcept C176290653 @default.
• W4282938802 hasConcept C181199279 @default.
• W4282938802 hasConcept C182979987 @default.
• W4282938802 hasConcept C185592680 @default.
• W4282938802 hasConcept C190283241 @default.
• W4282938802 hasConcept C203014093 @default.
• W4282938802 hasConcept C2778245361 @default.
• W4282938802 hasConcept C2778461978 @default.
• W4282938802 hasConcept C2778623314 @default.

• next